Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028860 | 0.83 | HTR2A (0.41) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7103560 | 0.79 | KDM4A (0.44) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7106088 | 0.79 | HTR2A (0.39) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7025857 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7030349 | 0.78 | HTR2A (0.43) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7026932 | 0.77 | OPRM1 (0.45) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7029318 | 0.76 | HTR2A (0.45) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7027762 | 0.75 | HTR2A (0.49) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL7027681 | 0.75 | HTR2A (0.49) | HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL10746648 | 0.74 | ALDH1A1 (0.43) | KDM4EALDH1A1GLAGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | MERCK PATENT GMBH (DE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | HTR2A, HTR1A, HTR5A | HTR2A 1/4885HTR2C 5/4885HTR7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.